

Please type a plus sign (+) inside the box →

PTO/SB/08B (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 09/735,989

Filing Date 12/13/2000

First Named Inventor Johan H. Geerke


Group Art Unit


Examiner Name Unknown

Attorney Docket Number ABC2040B1

Attorney Secret Number: **ARC2940R1**

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Y. W. FRANCIS LAM, "Stereoselectivity: An Issue of Significant Importance in Clinical Pharmacology," <i>Pharmacotherapy</i> , Vol. 8 (No. 3), p. 147-157, (January 4, 1988).	
	2	KENNETH WILLIAMS AND EDMUND LEE, "Importance of Drug Enantiomers in Clinical Pharmacology," <i>Drugs</i> , ADIS Press Limited (U.S.), p. 333-354, (January 4, 1985).	
		 JAN 16 2001 JC147 PATENT & TRADEMARK OFFICE	



Examiner Signature **Date Considered**

considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Petitions, Washington, DC 20231.